The choice for BCMA, already discovered in 1992 as a translocation counterpart with the IL2 gene in a patient with T-cell lymphoma, as a prime target for CAR T-cells was obvious, because BCMA is normally expressed solely on a subset of mature B-cells and on antibody-producing plasma cells, including their malignant counterparts, the MM cells. Here, TNFRSF17 is linked to T-cell non-Hodgkin lymphoma.